ArticleCancer management and research2022
Factors of Recurrence After Complete Response in Children with Neuroblastoma: A 16-Year Retrospective Study of 179 Cases.
Article in Cancer management and research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Neuroblastoma cell growth and invasiveness is modulated by the activity of N-acetylglucosaminyltransferase-III.PloS one · 2026Article
- Review
- NONO Maintains SREBP-Regulated Cholesterol Biosynthesis via RNA Binding in Neuroblastoma.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025Article
- Reduction of N-Acetylglucosaminyltransferase-I Activity Promotes Neuroblastoma Invasiveness and EGF-Stimulated Proliferation In Vitro.International journal of translational medicine (Basel, Switzerland) · 2024Article
- Serum cholesterol level as a predictive biomarker for prognosis of Neuroblastoma.BMC pediatrics · 2024Article
- Article
- Mucoepidermoid carcinoma of the palate in a patient with a history of neuroblastoma: A case report and a review of the literature.Clinical case reports · 2023Article
- Identification of a novel eighteen-gene signature of recurrent metastasis neuroblastoma.Journal of molecular medicine (Berlin, Germany) · 2023Article
- A novel nomogram for predicting post-recurrence survival in recurrent neuroblastoma patients.American journal of cancer research · 2023Article
- Article
- [Clinical efficacy of combined therapy in children with stage 4 neuroblastoma].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2022Article
- Recurrent High-Risk Neuroblastoma in an Adult Woman 28 Years following Curative Treatment.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIt is not clear which known adverse prognostic factors of neuroblastoma are closely associated with tumor recurrence after complete response. We analyzed the factors for post-remission recurrence in children with neuroblastoma through a retrospective study.
methodsA total of 179 children with neuroblastoma who achieved initial complete response were included in this study. Kaplan-Meier method and multivariate Cox regression model were used to assess the factors that may have impact on tumor recurrence after complete response.
resultsThe 5-year overall survival rates of the entire cohort (n = 179), recurrence group (n = 86) and non-recurrence group (n = 93) were 81.9%, 66.2%, and 98.7%, respectively. The 5-year recurrence-free survival (RFS) rates of the entire cohort and the high-risk cohort were 47.3% and 31.2%, respectively. RFSs were significantly reduced in children with age ≥18 months, INSS stage 4, unfavorable histology, bone marrow metastasis, osseous metastasis, serum NSE level ≥100 ng/mL, and serum LDH level ≥1400 U/L (
conclusionAge ≥18 months, unfavorable histology, and serum LDH level ≥1400 U/L are independent risk factors for post-remission recurrence in children with neuroblastoma. A newly established recurrence risk stratification has diagnostic advantages in predicting risk of recurrence, which is especially suitable for low- and middle-income countries or regions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.